Short Interest in Generation Bio Co. (NASDAQ:GBIO) Decreases By 10.8%

Generation Bio Co. (NASDAQ:GBIO) saw a significant decrease in short interest in November. As of November 15th, there was short interest totalling 1,480,000 shares, a decrease of 10.8% from the October 31st total of 1,660,000 shares. Based on an average daily volume of 129,800 shares, the days-to-cover ratio is presently 11.4 days. Approximately 3.2% of the company’s shares are short sold.

Wall Street Analyst Weigh In

Several research analysts have issued reports on GBIO shares. Wedbush reiterated an “outperform” rating and set a $5.00 target price on shares of Generation Bio in a report on Thursday, November 7th. Needham & Company LLC reissued a “buy” rating and issued a $10.00 price objective on shares of Generation Bio in a research note on Wednesday, October 23rd.

Generation Bio Price Performance

GBIO traded down $0.05 on Tuesday, hitting $1.37. The company had a trading volume of 403,896 shares, compared to its average volume of 182,021. The stock has a fifty day moving average price of $2.09 and a 200-day moving average price of $2.55. Generation Bio has a 12-month low of $1.24 and a 12-month high of $4.65.

Institutional Investors Weigh In On Generation Bio

A number of hedge funds and other institutional investors have recently bought and sold shares of GBIO. Barclays PLC boosted its position in Generation Bio by 165.5% in the 3rd quarter. Barclays PLC now owns 76,430 shares of the company’s stock worth $189,000 after purchasing an additional 47,639 shares in the last quarter. State Street Corp boosted its stake in Generation Bio by 1.2% during the 3rd quarter. State Street Corp now owns 992,188 shares of the company’s stock worth $2,451,000 after purchasing an additional 11,669 shares during the last quarter. Baker BROS. Advisors LP grew its stake in Generation Bio by 61.1% during the 3rd quarter. Baker BROS. Advisors LP now owns 1,944,945 shares of the company’s stock valued at $4,804,000 after acquiring an additional 737,988 shares in the last quarter. FMR LLC increased its holdings in shares of Generation Bio by 0.3% in the third quarter. FMR LLC now owns 5,320,266 shares of the company’s stock valued at $13,141,000 after purchasing an additional 15,656 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Generation Bio by 2.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 423,299 shares of the company’s stock valued at $1,046,000 after acquiring an additional 8,692 shares during the last quarter. Hedge funds and other institutional investors own 95.22% of the company’s stock.

About Generation Bio

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.